Xin Lang Cai Jing·2026-03-27 06:53Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, and a cumulative increase of 6.82% over the past three days [1][4]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][5]. - The main business activities include I-IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][5]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [5]. Fund Holdings - Three funds under Qianhai Kaiyuan hold a total of 2.0321 million shares of Tiger Med, with a floating profit of approximately 5.1614 million CNY based on the stock price increase [2][6]. - The largest holding is from Qianhai Kaiyuan Medical Health A, which holds 1.81 million shares, representing 9.38% of the fund's net value, with a floating profit of about 4.5974 million CNY [3][7]. - Qianhai Kaiyuan Public Health Stock A holds 206,500 shares, accounting for 8.98% of the fund's net value, with a floating profit of approximately 524,500 CNY [3][8]. - Qianhai Kaiyuan CSI Health Index holds 15,566 shares, representing 1.17% of the fund's net value, with a floating profit of around 39,500 CNY [3][8].